百济神州:百悦泽联合利妥昔单抗一线治疗套细胞淋巴瘤成人初治患者可降低43%疾病进展或死亡风险

智通财经
Jun 30
【百济神州:百悦泽联合利妥昔单抗一线治疗套细胞淋巴瘤成人初治患者可降低43%疾病进展或死亡风险】百济神州公告,公司产品百悦泽 的3期临床研究MANGROVE取得积极结果。该研究旨在评估百悦泽 联合利妥昔单抗,对照苯达莫司汀联合利妥昔单抗,用于套细胞淋巴瘤成人初治患者一线治疗的效果。在此次预设的期中分析中,MANGROVE研究达到主要终点PFS。经独立审查委员会评估,相较BR方案,百悦泽 联合利妥昔单抗在PFS方面取得具有高度统计学显著性与临床意义的改善。数据显示,基于百悦泽 的无化疗方案可使疾病进展或死亡风险降低43%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10